TheraVet SA's latest marketcap:
As of 04/23/2025, TheraVet SA's market capitalization has reached $332,127.11. According to our data, TheraVet SA is the 48589th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 332,127.11 |
| Revenue (ttm) | 1.04 M |
| Net Income (ttm) | 0 |
| Shares Out | 3.57 M |
| EPS (ttm) | 0 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
TheraVet SA's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 04/23/2025 | €292,672 | -21.9% |
| 12/31/2024 | €374,763 | -91.98% |
| 12/29/2023 | €4.67 M | -42% |
| 12/30/2022 | €8.06 M | -56.14% |
| 12/31/2021 | €18.38 M |
Company Profile
TheraVet SA: Veterinary Biotechnology Solutions
TheraVet SA is a pioneering veterinary biotechnology company specializing in osteoarticular treatments for animals. Operating across Belgium, France, Switzerland, the United Kingdom, and the United States, the company focuses on improving animal health through innovative solutions.
Key Offerings
- BIOCERA-VET: An injectable self-hardening phosphocalcic bone void filler designed to promote osteointegration, osteoinduction, and bone remodeling.
- VISCO-VET: An injectable visco-regenerative gel formulated with hyaluronic acid, species-specific plasma, and an active pharmaceutical component.
Additional Products
- BIOCERA-VET Bone Surgery RTU: A ready-to-use, highly injectable calcium-phosphate cement for bone surgery applications.
- BIOCERA-VET SmartGraft: A naturally osteoconductive bone graft for enhanced healing.
- BIOCERA-VET Granules: An affordable, biocompatible calcium-phosphate bone substitute.
- BIOCERA-VET Osteosarcoma RTU: A ready-to-use injectable calcium-phosphate substitute for cementoplasty.
Target Conditions
TheraVet's products are primarily used to address:
- Osteoarthritis
- Ligament and tendon injuries
- Bone surgery in cats, dogs, and horses
Founded in 2017, TheraVet SA is headquartered in Gosselies, Belgium, and continues to advance veterinary care through cutting-edge biotechnology.
Frequently Asked Questions
-
What is TheraVet SA's (EPA-ALVET) current market cap?As of 04/23/2025, TheraVet SA (including the parent company, if applicable) has an estimated market capitalization of $332,127.11 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does TheraVet SA (EPA-ALVET) rank globally by market cap?TheraVet SA global market capitalization ranking is approximately 48589 as of 04/23/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.